CLINICAL TRIAL / NCT05061550

Inclusion Criteria: - Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB). - WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Adequate organ and bone marrow function. - Provision of tumour samples (newly acquired or archival tumour tissue [≤ 6 months old]) to confirm Programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) status. - Adequate pulmonary function. Exclusion Criteria: - Participants with sensitising EGFR mutations or ALK translocations. - Active or prior documented autoimmune or inflammatory disorders. - Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement. - History of another primary malignancy. - Participants with small-cell lung cancer or mixed small-cell lung cancer. - History of active primary immunodeficiency. - History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. - Participants who have preoperative radiotherapy treatment as part of their care plan. - Participants who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon at baseline, to obtain potentially curative resection of primary tumour. - QTcF (QT interval corrected by Fridericia's formula) interval ≥ 470 ms. - Any medical contraindication to treatment with chemotherapy as listed in the local labelling. - Participants with moderate or severe cardiovascular disease. - Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. - Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions. - Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Participants who received agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, and anti-LIF agents are also excluded. Participants who have received previous treatment with a TROP2 targeting ADC or with another ADC containing a chemotherapy agent that inhibits TOP1 activity are also excluded. - Current or prior use of immunosuppressive medication within 14 days before the first dose of study interventions. - Active or uncontrolled infections including HBA, HBV, HCV, and HIV.